Health Canada lukewarm on Vioxx panel findings

Murray, Sally
August 2005
CMAJ: Canadian Medical Association Journal;8/16/2005, Vol. 173 Issue 4, p350
Academic Journal
Deals with Health Canada's uncertainty on recommendations by an expert panel regarding the reintroduction of rofecoxib (Vioxx) on the Canadian market in 2005. Reason behind the withdrawal of the drug by Merck & Co. in September 2004; Comments from Marc Berthiaume, director of the Marketed Pharmaceuticals Division at Health Canada; Key to rofecoxib's reintroduction to the market.


Related Articles

  • Vioxx withdrawal spurs rivals into action. McGuire, Stephen // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p12 

    This article reports that in the wake of Merck & Co. Inc.'s decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/ Abbot Laboratories' stepped up efforts to promote their respective rival COX- 2 inhibitors, Celebrex and Mobic. Merck had pulled...

  • All Vioxx returns must be in by Sept. 30.  // Drug Topics;9/26/2005, Vol. 149 Issue 18, p8 

    This article reports that Merck & Co. Inc., which in 2004 announced the immediate and voluntary withdrawal of Vioxx, has informed pharmacists that in order to be eligible for reimbursement of returned Vioxx, all returns must be submitted no later than September 30, 2005.

  • Vioxx may return to Canadian market if requested?  // Reactions Weekly;7/16/2005, Issue 1060, p2 

    The article reports on the possibility of reintroducing Vioxx, a drug developed by Merck & Co., in the Canadian market, in July 2005. According to Marc Bertiaumine, director of the Canadian health department's marketed pharmaceuticals division, reintroduction of the drug is possible if the...

  • Approving New Medicines in Canada: Health Canada Needs a Dose of Competition. Graham, John R. // Fraser Forum;Jun2005, p9 

    Explores the drug approval process involved in the introduction of new drugs in Canada. Likelihood for Health Canada to enforce an automatic moratorium on the right of patients to use new drugs; Introduction of user fees and levies in order to recover the bureaucratic costs associated with drug...

  • Will 2005 Bring Drug Law Reform? Agres, Ted // Drug Discovery & Development;Jan2005, Vol. 8 Issue 1, p16 

    Presents views on the immediacy of a pharmaceutical reform law in the United States. Policies of the U.S. government under the administration of reelected President George W. Bush; Concern for patient safety from drugs resulting from the recall of the Vioxx drug developed by Merck & Co.Inc.;...

  • Patients Before Profits? Davies, Kevin // Bio-IT World;Dec2004, Vol. 3 Issue 12, p4 

    Comments on the decision of Merck to withdraw its sale of Vioxx, a drug inhibitor for arthritis, following the release of data stating that the drug promotes heart attack. Possible liability of the company to affected families; Results of a survey on the cardiovascular risk in patients who used...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;5/12/2012, Issue 1401, p4 

    This section offers news briefs related to the pharmaceutical industry, including the announcement by Health Canada that the labelling for Cipralex has been updated to warn of a dose-related risk of QT interval prolongation and the addition by Celgene Inc. of new safety information to the...

  • Propecia lawsuits: the lasting effects of delayed drug warnings. Collier, Roger // CMAJ: Canadian Medical Association Journal;7/9/2013, Vol. 185 Issue 10, pE455 

    The article reports the failure of the Canadian government agency Health Canada to promote the side effects of the Propecia drug used in the treatment of hair loss. It mentions that Finasteride, an active ingredient in the Propecia, is also present in the Proscar drug used to treat prostate...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jan2005, Vol. 4 Issue 1, p3 

    The article reports global developments related to the pharmaceutical industry. Continued controversies have prompted the U.S. Food and Drug Administration to implement extensive structural changes in order to avoid another scandal like the one experienced after Merck and Co. Inc.'s Vioxx was...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics